Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Development Of Recombinant Immunotherapeutics for Triple-Negative Breast Cancer (TNBC)
Breast cancer is the most common form of female malignancy globally. There are several subtypes of breast cancers including Triple-negative breast cancer (TNBC), which is mainly characterized by a lack of expression of the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Thesis |
| Language: | English |
| Published: |
Institute of Infectious Disease and Molecular Medicine
2024
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: Development Of Recombinant Immunotherapeutics for Triple-Negative Breast Cancer (TNBC)
- Next-Generation version of pseudomonas exotoxin a based immunotoxins with reduced immunogenicity for triple negative breast cancer (TNBC) treatment
- Establishment of enhanced protein purification strategies for recombinant immunotherapeutics
- Validation of an aASPH-SNAP-tag fusion protein for immunodiagnosis of triple-negative breast cancer
- Protein Kinase C‐Delta (PKCδ) inhibition stabilizes endothelium and suppresses triple‐negative breast cancer (TNBC) intravasation in a microfluidic hypoxic tumor model
- Lipid profile and atherogenic indices in triple-negative breast cancer
- Box-Behnken Design of Chitosan-NPs Encapsulating 5-Fluorouracil and Santalum album Essential Oil and Investigating their Combinatorial Therapeutic Effect against Triple Negative Breast Cancer (TNBC) cell line.